Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

1996 • 3,649 citations

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2003 • 3,532 citations

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.

1996 • 2,901 citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

2001 • 2,749 citations

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

2001 • 2,274 citations

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

2002 • 2,056 citations

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

2003 • 1,523 citations

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 • 1,349 citations

The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype

1994 • 1,109 citations

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

2005 • 1,039 citations

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

2002 • 923 citations

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

1977 • 888 citations

Dynamics of chronic myeloid leukaemia

2005 • 838 citations

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

2002 • 754 citations

Active transport of imatinib into and out of cells: implications for drug resistance

2004 • 650 citations

Clinical Pharmacokinetics of Imatinib

2005 • 625 citations

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

2003 • 554 citations

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

2002 • 534 citations

Bcrp1gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cellsin vivo

2002 • 506 citations

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

2006 • 433 citations

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

2004 • 415 citations

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

2005 • 348 citations

High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter

2004 • 338 citations

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

2004 • 324 citations

Unexpectedly Efficient Homing Capacity of Purified Murine Hematopoietic Stem Cells

2004 • 294 citations

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

2002 • 262 citations

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

2003 • 226 citations

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

2006 • 208 citations

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

2005 • 207 citations

Gefitinib reverses breast cancer resistance protein–mediated drug resistance

2004 • 190 citations

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

2006 • 165 citations

Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation

2003 • 160 citations

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

2001 • 159 citations

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

2005 • 157 citations

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

2006 • 149 citations

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL–expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

2006 • 149 citations

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

2006 • 146 citations

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells

2006 • 145 citations

Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571)

2003 • 117 citations

Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib

2004 • 107 citations

The Calcium Channel Blockers, 1,4-Dihydropyridines, Are Substrates of the Multidrug Resistance-Linked ABC Drug Transporter, ABCG2

2006 • 99 citations

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells

2005 • 77 citations

Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates

2004 • 69 citations

Enrichment of murine hemopoietic clonogenic cells by multivariate analyses and sorting.

1985 • 35 citations

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

2005 • 22 citations